ClinicalTrials.gg
CompletedNCT01712178Updated Jun 11, 2014Results posted

A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety

A Phase 2 interventional study of Adalimumab, current formulation and Adalimumab, new formulation in Rheumatoid Arthritis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 21 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-11.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies in Arthritis, Rheumatoid by AbbVie — 5 open to participants now, 6 under way, 1 of them phase 3. Arthritis, Rheumatoid · AbbVie.

Enrollment
24th of 38
100 · median 210
Started
2012
with 7 others
Phase 2
16 of 80
2 open now
Registered
29th of 80
by date

Among the 80 studies in Arthritis, Rheumatoid by AbbVie, this one is the 24th largest by enrollment of the 38 interventional ones that give a count, is one of 8 that started in 2012, is one of 16 in phase 2, and was the 29th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 80 studies in Arthritis, Rheumatoid by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Arthritis, Rheumatoid by AbbVie, or all of them as a file.
02

Study summary

A study in Rheumatoid Arthritis (RA) patients to evaluate two formulations of adalimumab for pharmacodynamics, pharmacokinetics, and safety.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Pharmacodynamic,Pharmacokinetic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject, 18 years or older who has a diagnosis of Rheumatoid Arthritis (RA) as defined by the 1987-revised American College of Rheumatology (ACR)-classification criteria or the new American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) diagnostic criteria for RA 2010-classification criteria and has a disease duration for a minimum of 3 months.
  • Subjects must be naïve to biologic therapy.
  • Subject must meet the following criteria for the joint assessment: • At least 6 swollen joints out of 66 assessed. • At least 6 tender joints out of 68 assessed.
  • Prior Disease Modifying Antirheumatic Drug (DMARD) therapy: a) Subjects not on methotrexate at baseline must remain without methotrexate throughout the study. Subjects on prior Methotrexate (MTX) must have discontinued at least 28 days prior to Week 0 (Day 1). b) Subjects on Disease Modifying Antirheumatic Drug (DMARD) therapy other than Methotrexate (MTX) (except prednisone/prednisolone less than or equal to 10 mg) must discontinue it for at least 28 days before the first dose of product at Week 0 (Day 1).
  • Female subjects are either not of , defined as for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy), or are practicing at least 1 of the following methods of throughout the study and for at least 150 days after the last dose of study drug: • Condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD). • Hormonal contraceptives for 90 days prior to study drug administration. • Vasectomized partner(s).
  • Subjects must be able and willing to self-administer subcutaneous (SC) injections or have a qualified person available to administer subcutaneous (SC) injections.
  • Subject is judged to be in good general health as determined by the Principal Investigator based upon the results of medical history, physical examination, laboratory profile, chest x-ray (CXR), and 12 lead (ECG) performed during Screening.
  • Subject has a negative Tuberculosis (TB) screening assessment (including a (Purified Protein Derivative (PPD) test or QuantiFERON-Tuberculosis (TB) Gold test or equivalent) and negative chest x-ray (Posterior-Anterior (PA) and lateral view) at Screening. If a subject has evidence of a latent Tuberculosis (TB) infection, the subject must initiate and complete a minimum of 2 weeks of anti-Tuberculosis (TB) therapy or have documented completion of a course of anti-Tuberculosis (TB) therapy prior to Baseline.
  • Subjects must be willing to provide written consent and to comply with the requirements of this study protocol.

Exclusion criteria

Exclusion Criteria:

  • Subject has been treated with intra-articular or parenteral administration of in the preceding 4 weeks from Baseline visit. Inhaled corticosteroids for stable medical conditions are allowed. Oral of less than or equal to 10 mg/d prednisone equivalent are allowed.
  • Subject has been treated with any drug of a chemical or biological nature within a minimum of 30 days or 5 half-lives (whichever is longer) of the drug prior to Baseline Visit.
  • Subject has a history of acute inflammatory joint disease of different origin other than Rheumatoid Arthritis (RA) (e.g., seronegative spondyloarthropathy, psoriatic arthritis, Reiter's syndrome, systemic lupus erythematosus, gouty arthritis, or any arthritis with onset prior to age 17 years).
  • Known to adalimumab or its .
  • Subject currently uses or plans to use anti-retroviral therapy at any time during the study.
  • History of demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease.
  • History of invasive infection (e.g., listeriosis and histoplasmosis), human immunodeficiency syndrome ().
  • Chronic recurring infections or active Tuberculosis (TB).
  • History of moderate to severe congestive heart failure ( (NYHA) class III or IV), recent cerebrovascular accident and any other condition which, in the opinion of the investigator, would put the subject at risk by participation in the protocol.
  • Evidence of dysplasia or history of (including lymphoma and leukemia) other than a successfully treated non- cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix.
  • Subject received any within 3 months prior to study drug administration. - Subject has a history of hematologic (e.g., severe anemia, leukopenia, thrombocytopenia), renal or liver disease (e.g., fibrosis, cirrhosis, hepatitis).
  • Positive pregnancy test at Screening or Baseline.
  • Subject is considered by the investigator, for any reason, to be unsuitable candidate for the study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    New formulation of adalimumab 40 mg every other week

    New formulation adalimumab 40 mg every other week

    Biological: Adalimumab, new formulation

  • Active comparator
    Current formulation adalimumab 40 mg every other week

    Current formulation adalimumab 40 mg every other week

    Biological: Adalimumab, current formulation

Interventions

  • Current formulation adalimumab 40 mg every other week

    Also known as: Humira

  • BiologicalAdalimumab, new formulation

    New formulation adalimumab 40 mg every other week

06

What researchers measure

Primary outcomes

  1. Serum Concentrations of Adalimumab at Weeks 12 and 24

    Blood samples for adalimumab analysis were collected by venipuncture and serum concentrations of adalimumab were determined using a validated enzyme-linked immunoadsorbent assay (ELISA) method.

    Time frame: Measured at Weeks 12 and 24

  2. Mean Disease Activity Scores (DAS28) at Weeks 12 and 24

    The Disease Activity Score (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

    Time frame: Measured at Weeks 12 and 24

Secondary outcomes

  1. Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Weeks 12 and 24

    American College of Rheumatology 20% (ACR20) response. A participant is a responder if the following 3 criteria for improvement from baseline are met: * ≥ 20% improvement in tender joint count; * ≥ 20% improvement in swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * CRP (Acute phase reactant (Erythrocyte sedimentation rate/C-reactive protein))

    Time frame: Measured at Weeks 12 and 24

  2. Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Weeks 12 and 24

    American College of Rheumatology 50% (ACR50) response. A participant is a responder if the following 3 criteria for improvement from baseline are met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * CRP (Acute phase reactant (Erythrocyte sedimentation rate/C-reactive protein))

    Time frame: Measured at Weeks 12 and 24

  3. Mean Health Assessment Questionnaire (HAQ-DI) Scores at Weeks 12 and 24

    The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is ≥0.22. HAQ remission indicating normal physical function is defined by HAQ-DI \< 0.5.

    Time frame: Measured at Weeks 12 and 24

  4. Mean Short Form-36 (SF-36) Physical Component Summary Scores and Mental Component Summary Scores at Weeks 12 and 24

    The Short Form 36 (SF-36) determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the physical component summary score (PCS) of the SF-36. Items 5-8 primarily contribute to the mental component summary score (MCS) of the SF-36. Scores on each item are summed and averaged (range = 0 (maximum disability) - 100 (no disability). The standard recall period is four weeks.

    Time frame: Measured at Weeks 12 and 24

  5. Percentage of Participants Positive for Anti-adalimumab Antibody

    Percentage of participants with anti-adalimumab antibody

    Time frame: Measured through Week 24

  6. Number of Participants With Adverse Events

    An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. See the Reported Adverse Events Section for more details.

    Time frame: From time of informed consent to 70 days following the last dose of study drug

  7. Mean Injection Site Pain on a Visual Analogue Scale (VAS)

    The Visual Analogue Scale (VAS) consisted of a horizontal 100 mm line, with 0 representing "no pain" and 100 representing "worst possible pain". Participants placed a mark on the line representing their current level of pain immediately after injections on Day 1 of the study.

    Time frame: Immediately after injections on Day 1

07

Results

Posted Jun 11, 2014

Participant flow

Participant flow — Overall Study
MilestoneNew Formulation of Adalimumab 40 mg Every Other WeekCurrent Formulation Adalimumab 40 mg Every Other Week
Started5050
Completed4947
Not completed13
Withdrew: Withdrew consent due to an adverse event11
Withdrew: Serious adverse event/withdrew consent01
Withdrew: Lost to follow-up01

Outcome measures

PrimarySerum Concentrations of Adalimumab at Weeks 12 and 24

Blood samples for adalimumab analysis were collected by venipuncture and serum concentrations of adalimumab were determined using a validated enzyme-linked immunoadsorbent assay (ELISA) method.

Time frame:
Measured at Weeks 12 and 24
Reported as:
Mean · µg/mL
Serum Concentrations of Adalimumab at Weeks 12 and 24
µg/mLNew Formulation of Adalimumab 40 mg Every Other WeekCurrent Formulation Adalimumab 40 mg Every Other Week
Week 12: n= 46 (new), n=43 (current)5.72 ± 4.496.23 ± 4.29
Week 24: n= 47 (new), n=41 (current)5.95 ± 5.136.17 ± 4.50
PrimaryMean Disease Activity Scores (DAS28) at Weeks 12 and 24

The Disease Activity Score (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

Time frame:
Measured at Weeks 12 and 24
Reported as:
Least squares mean · units on a scale
Mean Disease Activity Scores (DAS28) at Weeks 12 and 24
units on a scaleNew Formulation of Adalimumab 40 mg Every Other WeekCurrent Formulation Adalimumab 40 mg Every Other Week
Week 123.78 ± 0.1473.82 ± 0.148
Week 243.54 ± 0.1523.46 ± 0.153
SecondaryPercentage of Participants With an American College of Rheumatology (ACR) 20 Response at Weeks 12 and 24

American College of Rheumatology 20% (ACR20) response. A participant is a responder if the following 3 criteria for improvement from baseline are met: * ≥ 20% improvement in tender joint count; * ≥ 20% improvement in swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * CRP (Acute phase reactant (Erythrocyte sedimentation rate/C-reactive protein))

Time frame:
Measured at Weeks 12 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Weeks 12 and 24
percentage of participantsNew Formulation of Adalimumab 40 mg Every Other WeekCurrent Formulation Adalimumab 40 mg Every Other Week
Week 1262.068.0
Week 2468.068.0
SecondaryPercentage of Participants With an American College of Rheumatology (ACR) 50 Response at Weeks 12 and 24

American College of Rheumatology 50% (ACR50) response. A participant is a responder if the following 3 criteria for improvement from baseline are met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * CRP (Acute phase reactant (Erythrocyte sedimentation rate/C-reactive protein))

Time frame:
Measured at Weeks 12 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Weeks 12 and 24
percentage of participantsNew Formulation of Adalimumab 40 mg Every Other WeekCurrent Formulation Adalimumab 40 mg Every Other Week
Week 1236.040.0
Week 2448.050.0
SecondaryMean Health Assessment Questionnaire (HAQ-DI) Scores at Weeks 12 and 24

The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is ≥0.22. HAQ remission indicating normal physical function is defined by HAQ-DI \< 0.5.

Time frame:
Measured at Weeks 12 and 24
Reported as:
Least squares mean · units on a scale
Mean Health Assessment Questionnaire (HAQ-DI) Scores at Weeks 12 and 24
units on a scaleNew Formulation of Adalimumab 40 mg Every Other WeekCurrent Formulation Adalimumab 40 mg Every Other Week
Week 121.10 ± 0.0751.02 ± 0.076
Week 241.01 ± 0.0820.97 ± 0.083
SecondaryMean Short Form-36 (SF-36) Physical Component Summary Scores and Mental Component Summary Scores at Weeks 12 and 24

The Short Form 36 (SF-36) determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the physical component summary score (PCS) of the SF-36. Items 5-8 primarily contribute to the mental component summary score (MCS) of the SF-36. Scores on each item are summed and averaged (range = 0 (maximum disability) - 100 (no disability). The standard recall period is four weeks.

Time frame:
Measured at Weeks 12 and 24
Reported as:
Least squares mean · units on a scale
Mean Short Form-36 (SF-36) Physical Component Summary Scores and Mental Component Summary Scores at Weeks 12 and 24
units on a scaleNew Formulation of Adalimumab 40 mg Every Other WeekCurrent Formulation Adalimumab 40 mg Every Other Week
PCS score- Week 1238.88 ± 0.95739.08 ± 0.974
PCS score- Week 2439.38 ± 1.04439.94 ± 1.022
MCS score- Week 1244.78 ± 1.17242.78 ± 1.192
MCS score- Week 2443.16 ± 1.24645.46 ± 1.267
SecondaryPercentage of Participants Positive for Anti-adalimumab Antibody

Percentage of participants with anti-adalimumab antibody

Time frame:
Measured through Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Positive for Anti-adalimumab Antibody
Percentage of participantsNew Formulation of Adalimumab 40 mg Every Other WeekCurrent Formulation Adalimumab 40 mg Every Other Week
Percentage of Participants Positive for Anti-adalimumab Antibody1416
SecondaryNumber of Participants With Adverse Events

An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. See the Reported Adverse Events Section for more details.

Time frame:
From time of informed consent to 70 days following the last dose of study drug
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsNew Formulation of Adalimumab 40 mg Every Other WeekCurrent Formulation Adalimumab 40 mg Every Other Week
Number of Participants With Adverse Events3134
SecondaryMean Injection Site Pain on a Visual Analogue Scale (VAS)

The Visual Analogue Scale (VAS) consisted of a horizontal 100 mm line, with 0 representing "no pain" and 100 representing "worst possible pain". Participants placed a mark on the line representing their current level of pain immediately after injections on Day 1 of the study.

Time frame:
Immediately after injections on Day 1
Reported as:
Mean · Millimeters
Mean Injection Site Pain on a Visual Analogue Scale (VAS)
MillimetersNew Formulation of Adalimumab 40 mg Every Other WeekCurrent Formulation Adalimumab 40 mg Every Other Week
Mean Injection Site Pain on a Visual Analogue Scale (VAS)14.4 ± 22.635.9 ± 29.2

Adverse events

Collected over Adverse events were collected from the time of study drug administration until 70 days following the last dose. Serious adverse events were collected from the time the participant signed the informed consent.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
New Formulation of Adalimumab 40 mg Every Other Week—0/50 (0%)23/50 (46%)
Current Formulation Adalimumab 40 mg Every Other Week—2/50 (4%)16/50 (32%)
Most frequent serious events
Most frequent serious events
EventNew Formulation of Adalimumab 40 mg Every Other WeekCurrent Formulation Adalimumab 40 mg Every Other Week
THORACIC VERTEBRAL FRACTUREInjury, poisoning and procedural complications0/501/50
TRANSITIONAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/501/50
Most frequent other events
Most frequent other events
EventNew Formulation of Adalimumab 40 mg Every Other WeekCurrent Formulation Adalimumab 40 mg Every Other Week
NASOPHARYNGITISInfections and infestations5/506/50
NAUSEAGastrointestinal disorders4/500/50
CYSTITISInfections and infestations4/502/50
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations4/504/50
RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders3/504/50
DYSPEPSIAGastrointestinal disorders3/501/50
INJECTION SITE REACTIONGeneral disorders3/500/50
SINUSITISInfections and infestations3/501/50
COUGHRespiratory, thoracic and mediastinal disorders3/501/50

Baseline characteristics

Age, Continuous
Age, Continuous(years)New Formulation of Adalimumab 40 mg Every Other WeekCurrent Formulation Adalimumab 40 mg Every Other WeekTotal
Mean55.5 ± 11.053.0 ± 12.354.3 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)New Formulation of Adalimumab 40 mg Every Other WeekCurrent Formulation Adalimumab 40 mg Every Other WeekTotal
Female414182
Male9918
08

Study locations

21 sites
  • Site Reference ID/Investigator# 75073
    Mesa, Arizona 85202, United States
  • Site Reference ID/Investigator# 75077
    Hemet, California 92543, United States
  • Site Reference ID/Investigator# 75076
    Wichita, Kansas 67203, United States
  • Site Reference ID/Investigator# 75075
    Clifton, New Jersey 07012, United States
  • Site Reference ID/Investigator# 83133
    Philadelphia, Pennsylvania 19152, United States
  • Site Reference ID/Investigator# 75074
    Charleston, South Carolina 29406, United States
  • Site Reference ID/Investigator# 75100
    Brussels, 1200, Belgium
  • Site Reference ID/Investigator# 75101
    Liege, 4000, Belgium
  • Site Reference ID/Investigator# 75104
    Brno, 638 00, Czech Republic
  • Site Reference ID/Investigator# 76788
    Prague 2, 128 50, Czech Republic
  • Site Reference ID/Investigator# 75102
    Uherske Hradiste, 686 01, Czech Republic
  • Site Reference ID/Investigator# 75103
    Zlin, 760 01, Czech Republic
  • Site Reference ID/Investigator# 78014
    Ratingen, 40882, Germany
  • Site Reference ID/Investigator# 75079
    Caguas, 00725, Puerto Rico
  • Site Reference ID/Investigator# 75078
    Vega Baja, 00693, Puerto Rico
  • Site Reference ID/Investigator# 76787
    Bucharest, 020475, Romania
  • Site Reference ID/Investigator# 75978
    Cluj-Napoca, 400006, Romania
  • Site Reference ID/Investigator# 76433
    Ploiesti, 100337, Romania
  • Site Reference ID/Investigator# 76934
    Banska Bystrica, 97405, Slovakia
  • Site Reference ID/Investigator# 76935
    Senica, 905 01, Slovakia
  • Site Reference ID/Investigator# 76682
    Zilina, 010 01, Slovakia
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2012
First posted
Oct 23, 2012
Start
Jun 2012
Primary completionActual
May 2013
CompletionActual
May 2013
Results first posted
Jun 11, 2014
Last update
Jun 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01712178
Responsible party
Sponsor
First posted
Oct 23, 2012
Start date
Jun 2012
Primary completion
May 2013
Completion
May 2013
Results posted
Jun 11, 2014
Last update
Jun 11, 2014

Study contacts

Andy Payne, PhD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion